Source-grounded facts extracted from BioXcel Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BioXcel Therapeutics, Inc. reported financial results for for the three months and year ended December 31, 2025.
“On March 27, 2026, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2025 and provided a business update.”
BioXcel Therapeutics, Inc. amended Warrant Amendment Agreement with the Purchaser valued at approximately $173,135 (effective 2026-03-10).
“In connection with the Offering, pursuant to the terms of a Warrant Amendment Agreement, dated as of March 10, 2026 (the “Warrant Amendment Agreement”), the exercise price of certain outstanding warrants issued on March 27, 2024 and November 25, 2024 to purchase up to an aggregate of 1,385,083 shares of Common Stock held by the Purchaser was reduced to $1.614 per share”
BioXcel Therapeutics, Inc. entered into Purchase Agreement with the Purchaser valued at approximately $7.8 million (effective 2026-03-10).
“On March 10, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser named therein”
Dr. Rajiv Patni was appointed as Director at BioXcel Therapeutics, Inc..
“On January 15, 2025, the Board appointed Dr. Rajiv Patni to the Board, effective January 15, 2025.”
David Mack was appointed as Director at BioXcel Therapeutics, Inc..
“On November 21, 2024, the Board appointed David Mack to the Board, effective as of November 21, 2024.”
Matthew Wiley departed as Senior Vice President and Chief Commercial Officer at BioXcel Therapeutics, Inc..
“Matthew Wiley, Senior Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the “ Company ”), and the Company agreed that Mr. Wiley would cease his employment with the Company, effective October 2, 2024”
Matt Wiley departed as Chief Commercial Officer at BioXcel Therapeutics, Inc..
“On September 18, 2024, the Company notified Matt Wiley, the Company’s Chief Commercial Officer, that, in connection with the Clinical Prioritization, his position was being eliminated.”
BioXcel Therapeutics, Inc. reported first quarter of 2024 results: revenue $582,000, net income $26.8 million.
“of BXCL701 and KEYTRUDA® (pembrolizumab) in metastatic pancreatic ductal adenocarcinoma (PDAC). First Quarter 2024 Financial Results Net Revenue: Net revenue from IGALMI was $582,000 for the first quarter of 2024, compared to $206,000 for the same period in 2023, representing a 182% increase. Sequential quarterly revenue increased 55% in Q1 2024 from the”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.